A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.
Anusha KalbasiMitchell KamravaFritz Christian EilberDonatello TelescaRitchell Van DamsYingli YangDan RuanScott D NelsonSarah M DryJackie HernandezBartosz ChmielowskiArun S SinghSusan V BukataNicholas M BernthalMichael L SteinbergJoanne B WeidhaasPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
A shorter 5-day neoadjuvant RT regimen results in favorable rates of wound complications and grade ≥2 toxicity after 2-year follow-up. Five-day RT significantly increased utilization of neoadjuvant RT at our high-volume sarcoma center. With further validation, a putative germline biomarker for wound complications may guide safer RT utilization.